NEFL and early-onset autosomal dominant Alzheimer disease: In an effort to determine whether magnitude of VSI is a novel and early biomarker of mild stage Alzheimer’s disease, the current study will also assess plasma-based total and phosphorylated Tau, neurofilament (NfL) and (ApoE).